Dr. Amrit Pattojoshi


MBBS, D.P.M. (Psychiatry), M.D. (Psychiatry)

Clinician (Neuro-psychiatrist), Educator, Social reformer, Speaker, Writer

  • Specialization: Psychiatrists
  • Email: dramritp@yahoo.com
  • Registration No: 14110/OMC




Research Details

For Online or Offline Consultation

Book An Appointment


Medication Management

Dr. Amrit Pattojoshi, a psychiatrist, provides meticulous medication management utilizing psychopharmacological interventions, conducting comprehensive assessments, prescribing appropriate medications, and monitoring treatment efficacy.


Dr. Amrit Pattojoshi, a psychiatrist, offers individualized psychotherapy sessions employing integrative modalities such as cognitive-behavioral therapy (CBT), psychodynamic therapy, and interpersonal therapy.


Dr. Amrit Pattojoshi, a psychiatrist, provides meticulous psychiatric evaluations utilizing standardized diagnostic criteria and comprehensive medical histories to discern and categorize mental health disorders accurately.


Drug Addiction

Dr. Amrit Pattojoshi, a psychiatrist, implements a comprehensive treatment plan involving pharmacotherapy, behavioral therapies, and relapse prevention strategies to address Substance Use Disorder, aiming to mitigate drug cravings, promote abstinence, and facilitate long-term recovery.

Sleep & Sexual Disorder

Dr. Amrit Pattojoshi, a psychiatrist, employs evidence-based interventions, including sleep hygiene techniques, cognitive-behavioral therapy (CBT), and pharmacotherapy, to address Sleep & Sexual Disorders, aiming to improve sleep quality and enhance sexual functioning.

Depression & Mood Disorder

Dr. Amrit Pattojoshi, a psychiatrist, employs a multimodal approach involving psychopharmacology and evidence-based psychotherapy to address Depression & Mood Disorders, aiming to restore neurochemical balance and enhance emotional well-being.


Dr. Amrit Pattojoshi, a psychiatrist, utilizes a comprehensive treatment regimen involving antipsychotic medications, cognitive remediation, and psychosocial interventions to manage Schizophrenia and optimize patients' psychopathological symptoms and functional outcomes.

Anxiety disorder

Dr. Amrit Pattojoshi, a psychiatrist, employs a multimodal therapeutic approach, combining anxiolytic medications, cognitive-behavioral therapy (CBT), and relaxation techniques to alleviate symptoms and enhance overall functioning in patients with Anxiety Disorders.

Dementia, Autism and ADHD

Dr. Amrit Pattojoshi, a psychiatrist, utilizes tailored treatment plans involving cognitive enhancers, behavioral interventions, and psychoeducation to manage Dementia, Autism Spectrum Disorder (ASD), and Attention-Deficit/Hyperactivity Disorder (ADHD).


My Mother was suffering for last 3 months, once I visited Dr. Amrit and that was all.. I will highly recommend if it is Neuro case. Thanks

Rabindra Kumar Moharana


One of the best doctor and a nice human I have ever met. He makes the patient comfortable to discuss and very fast to find out the problem.



Dr Pattojoshi I convey my highest regards for your magic hand and critical analysis for cure of my drastic of o c d condition

Sridhar Mishra



  • All
  • Images
  • Videos

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Dr Amrit Pattojoshi | Psychiatrist | Bhubaneswar

05-Jun-2023 15:56

Symptoms of Depression; Odia Psychiatrist Doctor Talks about Mental Health, 07-Jul-2023 00:01
How to deal with Anxiety By Dr. Amrit Pattjoshi, 06-Jul-2023 23:45
Centre calls same-sex marriage "urban, elitist concept" | Dr Amrit Pattojoshi | Faye D'Souza, 07-Jul-2023 00:01
Psychiatric is not a disease, It is matter of feeling and less of thoughts || Dr. Amrit Pattajoshi, 06-Jul-2023 23:45
Hello Doctor || Guest-Dr.Amrit Pattojoshi (Neuro Psychiatrist)|| MBCTv, 06-Jul-2023 23:45
Women mental Health Live With Dr Amrit Pattojoshi, 07-Jul-2023 00:01
DRUG ABUSE SPECIAL: How your psychiatrist can help in quitting addiction, 07-Jul-2023 00:01
Amna Samna | Odia Psychiatrist Dr. Amrit Pattyoshi Talks about Mental Health and Depression, 07-Jul-2023 00:01
Mob Mentality in the current Anno Domini Era | Dr. Amrit Pattojoshi | TEDxMKCG, 07-Jul-2023 00:01
Sex Education Is Important - Dr. Amrit Pattojoshi, 07-Jul-2023 00:01
Mental Health Red Alert : Odisha Sees Sharp Rise In Suicides, 07-Jul-2023 00:01
Doctor with Excellence and Selflessness |Dr Amrit Pattojoshi |neuropsychiatric | Social changer, 07-Jul-2023 00:01
Dr Amrit Pattojoshi on Bipolar Disorder in Odia, 07-Jul-2023 00:01
Health Tips | Dr.Amrit Pattojoshi | Dharitri Live, 07-Jul-2023 00:01
Understanding & Creating One's True Self In The Contemporary World | Dr. Amrit Pattojoshi | TEDxXUB, 06-Jul-2023 23:45
ANGER: How to manage it? When to seek help?, 07-Jul-2023 00:01
Dr Amrit Pattojoshi on Causes & Treatment of Eating Disorder, 07-Jul-2023 00:01


  • Images
  • Videos




Digital Mental Health Revolution

As we continue to embrace the digital era, innovative technologies are revolutionizing various aspects of our lives, including mental health interventions. Today, we delve into the fascinating world of digital mental health interventions, exploring their efficacy, ethical considerations, and potential future implications, as presented by the esteemed Dr. Amrit Pattojoshi. So, let's dive in!

Digital mental health interventions, also known as e-mental health, encompass a wide range of online platforms, apps, and programs designed to support mental health and well-being. These tools offer accessible and convenient ways for individuals to receive therapeutic support, manage their mental health conditions, or simply foster a positive state of mind.

1. Efficacy of Digital Mental Health Interventions:

Numerous studies have shown promising results regarding the effectiveness of digital mental health interventions. These platforms offer evidence-based therapies, such as Cognitive Behavioral Therapy (CBT), Mindfulness-Based Cognitive Therapy (MBCT), and Dialectical Behavior Therapy (DBT). They provide interactive modules, exercises, and support tools that can be customized to the individual's needs.

Research suggests that digital interventions can yield significant improvements in anxiety, depression, stress, and overall well-being. They are particularly helpful for individuals who may face barriers to accessing traditional in-person therapy, such as geographical limitations, financial constraints, or the stigma associated with seeking mental health support.

However, it's essential to note that digital interventions may not be suitable for everyone. In some cases, face-to-face therapy may be more appropriate, especially for individuals with severe mental health conditions or those who require specialized care.

2. Ethical Considerations:

With the proliferation of digital mental health interventions, several ethical concerns have emerged. Ensuring data privacy and security is of utmost importance when dealing with sensitive mental health information. Dr. Amrit Pattojoshi emphasizes the significance of transparent privacy policies, encrypted communication channels, and secure servers to safeguard users' data.

Moreover, issues surrounding informed consent, confidentiality, and the potential risk of misdiagnosis demand careful attention. As these interventions increasingly employ artificial intelligence and machine learning algorithms, it becomes crucial to strike a balance between personalization and protecting the user's privacy.

3. Future Implications:

The future of digital mental health interventions appears promising. Advancements in technology and artificial intelligence will likely lead to even more sophisticated platforms with personalized interventions tailored to individual needs.

One exciting area of development is the use of virtual reality (VR) in mental health treatment. VR-based therapies offer immersive and controlled environments to help individuals confront and manage various psychological challenges, such as phobias and PTSD.

Additionally, the integration of wearable devices and biometric sensors holds the potential in providing real-time feedback to users and healthcare professionals, enhancing treatment efficacy.

However, as we embrace these exciting possibilities, it is crucial to maintain a human-centered approach. Digital interventions should complement, not replace, traditional mental health care and ethical guidelines must continually evolve to address emerging challenges.

In conclusion, digital mental health interventions present a revolutionary approach to enhancing mental health support. Backed by solid evidence, these interventions hold promise in reaching a broader population and breaking down barriers to access. However, it is essential to navigate the ethical landscape thoughtfully and cautiously as we continue to explore the potential of this evolving field. Dr. Amrit Pattojoshi's expertise sheds light on these important aspects, guiding us toward a future where technology and compassion work hand in hand to support mental well-being.

Read More



This article highlights the importance of medication adherence in the treatment of schizophrenia. Nonadherence to medication can lead to relapse and increased healthcare costs. Rates of non-compliance in psychotic disorders vary, and nonadherent patients have a higher risk of relapse compared to adherent patients. Poor adherence results in the underutilization of treatment resources and compounds the challenges of improving health, particularly in impoverished populations. Nonadherence in schizophrenia accounts for a significant portion of the costs of rehospitalization. Patients who experience a relapse often struggle to regain their pre-relapse level of social adjustment. Improving adherence is crucial and can be as impactful as the introduction of antipsychotic medications. Adherence is defined as the extent to which a person's behavior aligns with medical advice, involving multiple indicators of self-care. The World Health Organization has identified five dimensions of adherence, including socioeconomic, therapy-related, patient-related, illness-related, and healthcare team/system-related factors.


This study aimed to investigate the factors influencing medication adherence in schizophrenia and examine the relationship between illness severity, medication side effects, and adherence. The research was conducted at the Central Institute of Psychiatry (CIP) in Ranchi, India, which is a postgraduate teaching hospital specializing in psychiatric care. The study received approval from the institutional ethics committee.

A purposive sampling method was employed, and 60 adult patients within the age range of 18-55 years, meeting the criteria for schizophrenia according to ICD-10, DCR, and attending follow-up at CIP OPD, were included in the study. Individuals with comorbid mental retardation, personality disorders, or general medical illnesses requiring additional treatment were excluded.

Informed consent was obtained from the participants, and their socio-demographic profiles, including treatment history, cost, and availability of medication, were recorded using a specially designed datasheet. The severity of illness was assessed using the Brief Psychiatric Rating Scale (BPRS), which is an observer-rated scale developed by Overall & Gorham. The scale comprises 24 items rated on a 7-point severity scale.

Medication side effects were evaluated using the Udvalg For Kliniske Undersogelser (UKU) side effect scale, which is an observer-rated scale consisting of three parts: a single symptom rating scale, a scale for global assessment, and a scale for stating the consequences of side effects. A score of one or more on any item of the UKU side effect rating scale was considered for statistical analysis.

The participants' attitude toward adherence was assessed using the Medication Adherence Rating Scale (MARS) developed by Thomson. This scale combines two existing self-report measures of compliance, namely the Drug Attitude Inventory (DAI) and the Medication Adherence Questionnaire (MAQ). The MARS consists of 10 items requiring yes/no responses, and a higher total score indicates greater compliance, while a lower score indicates non-compliance.


The study involved 60 adult patients with schizophrenia, and various factors related to medication adherence were examined. The participants had a mean age of 31.58 years, with a majority being male (81.7%). Most of the participants were unemployed, and the mean duration of illness was 8.31 years. Paranoid schizophrenia was the most common diagnosis (58.3%), followed by undifferentiated schizophrenia (38.3%). Substance abuse was present in 10% of the sample.

Regarding medication, different types were prescribed, including atypical antipsychotics, typical antipsychotics, and additional medications. Most participants (71.7%) received medication under supervision. The mean duration of treatment was 5.04 years. The participants' attitude towards medication adherence, as assessed by the Medication Adherence Rating Scale (MARS), had a mean score of 7.63, indicating moderate adherence.

No significant associations were found between adherence and socio-demographic variables such as marital status, religion, educational level, or occupation. However, there was a trend suggesting poorer adherence among females. Factors such as family income, background, type of schizophrenia, past history, family history, substance abuse, medication type and route, cost, availability, supervision, and regularity of follow-ups did not show a significant relationship with adherence.

Correlation analysis revealed that medication adherence was negatively correlated with the severity of psychopathology, as measured by the Brief Psychiatric Rating Scale (BPRS), and certain side effects of medication, as assessed by the Udvalg For Kliniske Undersogelser (UKU) side effect rating scale. Specifically, adherence was negatively correlated with the UKU psychic side effect subscale and other side effect subscale, indicating that increased sleep duration, asthenia, lassitude, and increased fatigability were associated with poorer adherence.

Regression analysis further confirmed the impact of medication side effects on adherence. The UKU psychic side effect subscale, particularly increased sleep duration, was a significant predictor of poor adherence in the sample.

Overall, the study highlighted the importance of considering side effects and the severity of psychopathology in understanding medication adherence among individuals with schizophrenia.


The discussion highlights several findings and observations from the study. The rate of non-compliance in psychotic disorders was found to be 36.7%, which falls within the range reported in previous studies. No significant associations were found between adherence and socio-demographic variables.

The severity of psychopathology, as measured by the Brief Psychiatric Rating Scale (BPRS), was negatively correlated with adherence. This suggests that individuals with more severe symptoms may have more difficulty adhering to their medication regimen. Substance abuse did not significantly correlate with non-adherence in the sample, although previous studies have shown mixed results on the relationship between substance abuse and adherence.

No significant differences were observed in adherence between different types of antipsychotic medications (typical vs. atypical) or between oral and depot injectable formulations. The evidence regarding atypical antipsychotics and better compliance has been inconclusive in previous studies.

Adherence was negatively correlated with certain side effects of medication, such as increased sleep duration, asthenia, lassitude, and diminished sexual desire. Unwanted side effects can have a negative influence on adherence, particularly if they cause discomfort or dysphoric responses for the patient.

Regularity of follow-ups did not significantly impact adherence in the sample, although previous studies have suggested that regular visits to a psychiatrist can be correlated with better adherence.

Overall, the study contributes to our understanding of factors affecting medication adherence in schizophrenia. The findings highlight the importance of considering the severity of psychopathology and the impact of medication side effects in promoting adherence. However, the study has limitations, and further research is needed to explore additional factors influencing adherence in this population.


In conclusion, the study found that attitude towards adherence in schizophrenia correlated negatively with the severity of illness and certain side effects, including increased sleep duration, asthenia, increased fatigability, lassitude, and diminished sexual desire. Increased sleep duration and asthenia/lassitude/increased fatigability were identified as predictors of poor adherence in the patient population studied.

The study acknowledged some limitations, including a relatively small sample size and the potential exclusion of patients who did not visit a psychiatrist. The use of self-reported measures of compliance may have also led to an overestimation of adherence. Future studies should consider larger sample sizes, include patients from the community, and utilize additional measures of compliance, such as biochemical and physiological markers, pill counts, and electronic medication monitoring. Assessing therapist-related factors could also provide valuable information in understanding adherence in schizophrenia.

To know more about this article Click here
Read More

Research Paper

  1. Priyambada K; Pattojoshi A; Bakhla A. K (2017) A study of antenatal anxiety: comparison across trimesters; Int. Journal of Reproduction, Contraception, O&G, 6[5]
  2. Pattojoshi A; Motichand S [2016]Conceptual Issues in Mood Disorder: An Update; Odisha Journal of Psychiatry
  3. Lavania S; Khan A. H, Pattojoshi A (2017) Glucose Tolerance in the Probands of Deficit Schizophrenia and Nondeficit Schizophrenia; Schizophrenia Bulletin S177-S178
  4. Khan M. A., Das S, Pattojoshi A; et al. [2017] Self-reported depressive symptoms and anxiety among men with Urological Chronic Pelvic Pain Syndrome; Global Journal for Research Analysis, 6[11] 63-64
  5. Das S; Khan M.A.; Pattojoshi A; et al. [2017] Prevalence of sexual dysfunction in men with urological chronic pelvic pain syndromes; International Journal of Scientific Research, 6[11] 47-48
  6. Upadhyay N. U.; Pattojoshi A. [2017] CT Scan: A survey of myths; Paripex- Indian Journal of Research, 6[10] 78-79
  7. Kumar A; Upadhyay N. U.; Pattojoshi A.; et al. [2017] Pre-CT Scan anxiety among na�ve & patients with repeated scan; International Journal of Scientific Research, 6[11] 44-45
  8. Grover S, Avasthi A, Pattojoshi A [2016] Phenomenology and beliefs of patients with Dhat syndrome: A nationwide multicentric study; International Journal of Social Psychiatry, 62(1) 57-66
  9. Pattojoshi A, Pattanayak B.B., Ramakrishnan L [2017] LGBT Mental Health: The Way Forward; Odisha Journal of Psychiatry, 25(0975-122X) 02-08
  10. Mehta V.S, Pattojoshi A [2017] Metabolic Syndrome In Schizophrenia: An Overview Of Mechanisms; Odisha Journal of Psychiatry, 25(0975-122X) 10-19
  11. Pany S, Pattojoshi A, Ravan J.P.R [2017] Tardive Dystonia; Odisha Journal of Psychiatry, 25(0975-122X) 33-40
  12. Das T, Pattojoshi A [2017] Geriatric Psychiatry in India: An Overview of - Status, Concerns and Proposals; Odisha Journal of Psychiatry, 25(0975-122X) 41-45
  13. Kumari N, Pattojoshi A, Garg S [2017] Assessment of Marital Quality and Family Environment in Alcohol Dependence: A Cross Sectional Study; Odisha Journal of Psychiatry, 25(0975-122X) 56-67
  14. Pattajoshi A, Mehta V. S [2017] Internet and Role in Psychopathology; Odisha Journal of Psychiatry, 24(0975-122X) 01-03
  15. Pany S. K, Pattojoshi A, Das S [2017] Tardive Dyskinesia, A Critical Appraisal; Odisha Journal of Psychiatry, 24(0975-122X) 14-26
  16. Sahoo P, Pattojoshi A, Sethy R.R [2017] Social Factors in Mental Illness; Odisha Journal of Psychiatry, 24(0975-122X) 41-45
  17. Choudhary C, Pattojoshi A [2017] Suicidality in Lithium-Treated Patients with Bipolar Disorder; Odisha Journal of Psychiatry, 24(0975-122X) 51-55
  18. Kushwaha R, Singh P, Pattojoshi A [2017] The Phenomenological Experience of Gender Dysphoria Through Research; Odisha Journal of Psychiatry, 25(0975-122X) 92-98
  19. Singh P.S., Samantaray N. N., Pattojoshi A, et al. [2017] Cognitive Behaviour Therapy for the Management of Secondary Enuresis; Odisha Journal of Psychiatry, 24(0975-122X) 65-71
  20. Mishra J, Garg S, Pattojoshi A, et al. [2016] Psychological Assessment Basics: Revisited; Odisha Journal of Psychiatry 23(0975-122X) 
  21. Pattojoshi A, Ram D, et al [2010] Premorbid adjustment in bipolar comparison with schizophrenia; Indian Journal of Social Psychiatry
  22. Pattojoshi A [2016] Can Insurance not covering mental illness be called Health Insurance, Editorial in Odisha Journal of Psychiatry
  23. Tikka, Sai Krishna & Garg, Shobit & Pattojoshi A & Lahiri, Deyashini. (2022). ?Sax for Sex?: A Brief Narrative Review Exploring the Music-Sex Connect. Journal of Psychosexual Health. 4. 10.1177/26318318221088935.
  24. Tikka, Sai Krishna & Siddiqui, MAleem & Garg, Shobit & Pattojoshi A & Gautam, Manaswi. (2023). Clinical Practice Guidelines for the Therapeutic Use of Repetitive Transcranial Magnetic Stimulation in Neuropsychiatric Disorders. Indian Journal of Psychiatry. 65. 270. 10.4103/indianjpsychiatry.indianjpsychiatry_492_22.
  25. Saha, Gautam & Chakraborty, Kaustav & Pattojoshi, A. (2022). Management of Psychiatric Disorders in Patients with Stroke and Traumatic Brain Injury. Indian Journal of Psychiatry. 64. 344. 10.4103/indianjpsychiatry.indianjpsychiatry_34_22.
  26. Lahiri, Deyashini & Pujam, Nandha & Joseph, Geo & Pattojoshi, A. (2021). Psychological Outlook of Cinema. Eastern Journal of Psychiatry. 18. 30-38. 10.5005/EJP-18-1-30.
  27. Tikka, Sai Krishna & Parial, Sonia & Pattojoshi, A & Bagadia, Ashlesha & Prakash, Chandni & Lahiri, Deyashini & Jaiswal, Jyoti & Puri, Manju & Kukreti, Prerna & Behera, Rabindra & Agrawal, Sarita & Garg, Shobit & Dubey, Surabhi & Bajaj, Aakash & Agrawal, Akanksha & Singour, Chhaya & Patel, Geetanjali & Maghade, Megha & Purushotham A, Dr & Chandra, Prabha S.. (2021). Anxiety among pregnant women during the COVID-19 pandemic in India ? A multicentric study. Asian Journal of Psychiatry. 10.1016/j.ajp.2021.102880.
  28. Kumar, M. & Pattojoshi, A. (2021). Effectiveness and tolerability of eight-week treatment with dosulepin hydrochloride in patients with major depressive disorder not responding to four consecutive weeks of treatment with single selective serotonin reuptake inhibitor. International Journal of Advances in Medicine. 8. 10.18203/2349-3933.ijam20213642.
  29. Pattojoshi, A & Sidana, Aninda & Garg, Shobit & Mishra, Suvendu & Singh, Lokesh & Goyal, Nishant & Tikka, Sai Krishna. (2020). Staying home is NOT ?staying safe?: A rapid 8?day online survey on spousal violence against women during the COVID ?19 lockdown in India. Psychiatry and Clinical Neurosciences. 75. 10.1111/pcn.13176.
  30. Grover, Sandeep & Sahoo, Swapnajeet & Mehra, Aseem & Avasthi, Ajit & Tripathi, Adarsh & Subramanyam, Alka & Pattojoshi, A & Rao, GPrasad & Saha, Gautam & Mishra, KK & Chakraborty, Kaustav & Rao, NarenP & Vaishnav, Mrugesh & Singh, Om & Dalal, Pronob & Chadda, RakeshK & Gupta, Ravi & Gautam, Shiv & Sarkar, Siddharth & Reddy, YC. (2020). Comments on psychological impact of COVID-19 lockdown: An online survey from India. Indian Journal of Psychiatry. 62. 595. 10.4103/psychiatry.IndianJPsychiatry_1086_20.
  31. Pattojoshi, A & Tikka, Sai Krishna. (2020). School-based substance use disorder prevention in India: A brief appraisal. Indian Journal of Psychiatry. 62. 427. 10.4103/psychiatry.IndianJPsychiatry_43_19.
  33. Bakhla, Ajay & Pattojoshi, A& Priyambada, Krishna. (2020). PREVALENCE OF ANTENATAL ANXIETY AND DEPRESSION.
  34. Bhabani, Shankar & Bakhla, Ajay & Pattojoshi, A. (2020). HYPER SEXUALITY AND PSYCHOSIS AMONG MANIA WITH PSYCHOTIC SYMPTOMS. International Journal of Scientific Research.
  35. Bakhla, Ajay & Pattojoshi, A. (2020). PREVALENCE OF SEXUAL DYSFUNCTION IN MEN WITH UROLOGICAL CHRONIC PELVIC PAIN SYNDROMES (UCPPS). International Journal of Scientific Research.
  36. Bakhla, Ajay & Pattojoshi, A. (2020). SUICIDAL ATTEMPTS AND ITS CLINICAL CORRELATES.
  37. Bakhla, Ajay & Bhabani, Shankar & Pattojoshi, A. (2020). SYMPTOMS OF PERI ICTAL AND NON-EPILEPTIC PSYCHOSIS. International Journal of Scientific Research.
  38. Sarangi, Smita & Bakhla, Ajay & Priyambada, Krishna & Pattojoshi, A. (2020). PREVALENCE OF GESTATIONAL DIABETES.. International Journal of Scientific Research.
  39. Bakhla, Ajay & Pattojoshi, A. (2020). ORIGINAL RESEARCH PAPER PRE CT SCAN ANXIETY AMONG NA�VE AND PATIENTS WITH REPEATED SCAN. International Journal of Scientific Research.
  40. Priyambada, LateKrishna & Bakhla, Ajay & Pattojoshi, A. (2020). Factor structure and internal consistency of Oriya version of Edinburgh Postnatal Depression Scale. Indian Journal of Psychiatry. 62. 312. 10.4103/psychiatry.IndianJPsychiatry_631_19.
  41. Siddiqui, Shazia & Chauhan, Nidhi & Siddiqui, Mohd & Pattojoshi, A. (2020). Neurodevelopmental Disorders III: Intellectual Disability.
  42. Bakhla, Ajay & Pattojoshi, A. (2018). IMPULSIVITY AND METHODS OF SUICIDE.
  43. H, Amil & Pattojoshi, A & Siddiqui, Aleem & Lavania, Sagar & Dash, Lagnajit. (2017). DELUSIONAL DRUG DEPENDENCE- AN ENTITY. Journal of Evolution of Medical and Dental Sciences. 6. 5172-5176. 10.14260/jemds/2017/1123.
  44. Priyambada, Krishna & Pattojoshi, A & Bakhla, Ajay. (2017). A study of antenatal anxiety: comparison across trimesters. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 6. 10.18203/2320-1770.ijrcog20171504.
  45. Lavania, Sagar & Khan, Amil & Pattojoshi, A. (2017). SU46. Glucose Tolerance in the Probands of Deficit Schizophrenia and Nondeficit Schizophrenia. Schizophrenia Bulletin. 43. S177-S178. 10.1093/schbul/sbx024.044.

Read More

Mental Wellness at Work

In today's fast-paced and competitive work environment, the well-being of employees plays a crucial role in maintaining productivity and overall success in an organization. Dr. Amrit Pattojoshi, a renowned expert in the field of mental health, sheds light on the importance of addressing mental health in the workplace and how it can significantly impact employee well-being and productivity.

As a medical professional with a focus on mental health, Dr. Pattojoshi understands the intricate connection between mental health and job performance. Stress, anxiety, and depression are some of the common mental health issues affecting employees, which can lead to decreased productivity, increased absenteeism, and lower job satisfaction.

To create a supportive and nurturing work environment, employers must prioritize mental health initiatives. Here are some essential sub-points to consider:

Awareness and Education:

Dr. Pattojoshi emphasizes the need for awareness and education surrounding mental health in the workplace. Employers should provide training sessions that help employees recognize the signs of mental health struggles, both in themselves and their colleagues. Understanding the importance of seeking help and destigmatizing mental health concerns is critical.

Work-Life Balance:

Encouraging a healthy work-life balance is crucial for employee well-being. Employers should promote flexible work arrangements, and time-off policies, and encourage employees to disconnect from work when not on duty. This approach can help reduce stress and improve overall mental health.

Supportive Work Culture:

A supportive work culture can significantly impact an employee's mental health. Dr. Pattojoshi suggests fostering a culture that values open communication, empathy, and understanding. Providing access to counseling services and support groups can also be beneficial.

Reduce Workplace Stressors:

Identifying and addressing workplace stressors is vital to promote mental well-being. Dr. Pattojoshi advises employers to conduct regular stress assessments and implement strategies to minimize stress factors, such as workload management, clear communication channels, and conflict resolution mechanisms.

Encourage Physical Activity and Healthy Habits:

Physical health and mental health are closely intertwined. Encourage employees to engage in regular physical activity and adopt healthy habits like proper nutrition and sufficient sleep. These lifestyle choices can significantly impact an individual's mental well-being.

Implement Mental Health Policies:

Dr. Pattojoshi advocates for the implementation of mental health policies that promote a mentally healthy workplace. These policies may include flexible leave options, mental health days, and resources for seeking professional help.

Lead by Example:

Leaders and managers play a pivotal role in promoting a mentally healthy workplace. By demonstrating self-care and prioritizing their own mental well-being, they set a positive example for their team members.

In conclusion, Dr. Amrit Pattojoshi stresses the importance of integrating mental health initiatives into the workplace to promote employee well-being and productivity. By fostering a supportive culture, providing education and resources, and addressing workplace stressors, organizations can create a conducive environment for their employees to thrive both professionally and personally. 

Remember, "a healthy mind is the foundation for a successful workforce."
Read More



Plot no 14, reliance fresh, AG Colony, Unit 4, Bhouma Nagar, Bhubaneswar , Odisha, 751010


Not Available